Nikkei 225
38.236,07 -38,03 (-0,10%) Dow Jones 30
38.675,68 +449,98 (+1,18%) Bitcoin EUR
59.254,80 +5,64 (+0,01%) CMC Crypto 200
1.312,63 +35,65 (+2,79%) Nasdaq Compositive
16.156,33 +315,33 (+1,99%) S&P 500
5.127,79 +63,59 (+1,26%)
Genmab A/S (GMAB)
Nachbörse:
Genmab A/S
Carl Jacobsens Vej 30
Valby
Copenhagen 2500
Denmark
45 70 20 27 28
https://www.genmab.com
Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 2.286
Leitende Angestellte
| Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
|---|---|---|---|---|
| Dr. Jan G.J. van de Winkel Ph.D. | Co-Founder, President & CEO | 2,88M | N/A | 1961 |
| Mr. Anthony Pagano | Executive VP & CFO | 1,02M | N/A | 1978 |
Beschreibung
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
Corporate Governance
Genmab A/Ss ISS Governance QualityScore, Stand 1. Mai 2024, lautet 3. Die grundlegenden Scores sind Audit: 1, Vorstand: 1, Shareholderrechte: 1, Kompensation: 9.
